Galderma Posts 25% Sales Surge in Q1 2026 on Strong Dermatology Demand
Event summary
- Galderma reported Q1 2026 net sales of $1.473B, up 25.5% YoY at constant currency.
- Therapeutic Dermatology segment surged 71.3%, driven by Nemluvio's strong launch trajectory.
- Company completed full divestment by EQT-led consortium, marking largest fully monetized capital gain from a single private equity fund.
- Galderma issued €500M Eurobond in March to repay Term Loan and replaced Revolving Credit Facility with improved terms.
The big picture
Galderma's strong Q1 performance underscores the growing demand for specialized dermatology solutions, particularly in therapeutic treatments. The company's strategic focus on integrated dermatology is paying off, with broad-based growth across geographies and product categories. The completion of the EQT-led consortium divestment marks a significant milestone in Galderma's transition to a free-float dominated shareholder base, enhancing its financial flexibility and strategic optionality.
What we're watching
- Product Momentum
- Whether Galderma can sustain Nemluvio's rapid adoption in both prurigo nodularis and atopic dermatitis markets.
- Geographic Expansion
- The pace at which Galderma advances regulatory reviews for Nemluvio in additional top markets.
- Financial Strategy
- How Galderma's strengthened financial profile will support its ambitious growth targets amid volatile market conditions.
Related topics